ALK-ABELLO A/S announced the first market launch of EURNEFFY 2 mg (trade name for Neffy in the EU) in Germany. The introduction of this first adrenaline nasal spray for timely emergency treatment of anaphylaxis is an important milestone for adults and children (from 30 kg) with potentially life-threatening allergic reactions. With its intuitive, needle -free design, Eurneffy can help more people to use adrenaline safely in critical situations, to ensure quick and reliable emergency treatment and ultimately to improve and save the chances of a successful outcome.
Eurneffy offers a longer shelf life (30 months) and better temperature stability than existing adrenaline autoinjectors (AAIS). The EU approval is based on the evaluation of data from the EUR Neffy development program, in which more than 700 participants were involved. In clinical studies with Eurneffy, no serious undesirable events were reported.
The extensive clinical pharmacological data of EUR Neffy 2 mg were comparable to those of AAI, whereby the pharmacodynamics and pharmacokinetics were evaluated under different dosage conditions. Eurneffy with a dosage of 1 mg for patients with a body weight of 15 to 30 kg is currently undergoing an EU approval process that is expected to be completed in 2026. In Europe, anaphylaxis occurs annually at up to eight out of 100,000 people, and one of 300 people experiences it at some point in his life.
In emergency situations, uncertainty and hesitation in dealing with larger autoinjectors are obvious among those affected.
